A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors

Purpose This phase I trial was initiated to evaluate the safety, pharmacokinetics (PK) and maximum tolerated dose (MTD) of the glycolytic inhibitor, 2-deoxy- d -glucose (2DG) in combination with docetaxel, in patients with advanced solid tumors. Methods A modified accelerated titration design was us...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology Vol. 71; no. 2; pp. 523 - 530
Main Authors: Raez, Luis E., Papadopoulos, Kyriakos, Ricart, Alejandro D., Chiorean, E. Gabriella, DiPaola, Robert S., Stein, Mark N., Rocha Lima, Caio M., Schlesselman, James J., Tolba, Khaled, Langmuir, Virginia K., Kroll, Stewart, Jung, Donald T., Kurtoglu, Metin, Rosenblatt, Joseph, Lampidis, Theodore J.
Format: Journal Article
Language:English
Published: Berlin/Heidelberg Springer-Verlag 01.02.2013
Springer
Springer Nature B.V
Subjects:
ISSN:0344-5704, 1432-0843, 1432-0843
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first